Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis

PHASE2TerminatedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

July 26, 2017

Primary Completion Date

December 29, 2020

Study Completion Date

April 22, 2021

Conditions
Noninfectious Uveitis
Interventions
DRUG

Filgotinib

Tablet(s) administered orally

DRUG

Placebo to match filgotinib

Tablet(s) administered orally

DRUG

Prednisone

Tablet(s) administered orally

Trial Locations (24)

1050

Auckland Eye, Remuera

6009

Lions Eye Institute, Nedlands

19107

Mid Atlantic Retina, Philadelphia

27157

Wake Forest Baptist Medical Center, Winston-Salem

27710

Duke University Eye Center, Durham

44191

Cleveland Clinic Foundation-Cole Eye Institute, Cleveland

48073

Associated Retinal Consultants PC, Royal Oak

53705

university of Wisconsin-Madison, Madison

60304

Illinois Retina Associates, Oak Park

60611

Northwestern Medical Group, Chicago

76104

Texas Retina Associates - Fort Worth, Fort Worth

78240

Foresight Studies, LLC, San Antonio

80401

Colorado Retina Associates PC, Golden

91120

Hadassah Medical Center, Jerusalem

94303

Stanford Byers Eye Institute, Palo Alto

97239

Oregon Health Science University-Casey Eye Institute, Portland

02114

Ophthalmic Consultants of Boston, Boston

07650

Metropolitan Eye Research and Surgery Institute, Palisades Park

V5Z 0E9

Retina Consultants, Vancouver

Unknown

St. Franziskus Hospital, Münster

Moorfields Eye Hospital NHS Foundation Trust, London

L7 8XP

Royal Liverpool University Hospital, Liverpool

M13 9WL

Central Mancester Hospitals NHS Foundation Trust, Manchester Royal Eye Hospital, Manchester

OX3 9DU

Eye Research Group Oxford, Oxford Eye Hospital, Oxford

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

collaborator

Galapagos NV

INDUSTRY

NCT03207815 - Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis | Biotech Hunter | Biotech Hunter